DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on October 30, 2018, reports the cash position of DBV Technologies S.A. as of September 30, 2018. DBV Technologies is a biopharmaceutical company developing Viaskin, a proprietary epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company is headquartered in Montrouge, France, with shares traded on Euronext Paris (DBV) and Nasdaq (DBVT).
Key Financial Metrics
- Cash and Cash Equivalents: €153.9 million as of September 30, 2018.
- Outstanding Shares: 30,122,977 ordinary shares as of September 30, 2018.
- Fully Diluted Shares: 33,004,583 as of September 30, 2018.
- Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, net income, operating margins, or cash flow for the period.
- Debt and Liquidity: The filing text does not provide a clear value for total debt or specific liquidity ratios beyond the cash balance.
Material Changes
Cash and cash equivalents increased to €153.9 million as of September 30, 2018, compared to €137.9 million as of December 31, 2017. This represents an increase of €16.0 million in cash reserves over the nine-month period.
Outlook, Risks, and Management Commentary
The company continues clinical trials for Viaskin Peanut and Viaskin Milk, with preclinical development ongoing for Viaskin Egg. Additionally, DBV is pursuing a human proof-of-concept clinical study of Viaskin Milk for Eosinophilic Esophagitis and exploring applications in vaccines. The filing does not contain specific forward-looking guidance, risk factors, or discussion of unusual items beyond the standard description of its clinical pipeline.
Investor Verification Checklist
- Verify the €153.9 million cash balance against the company's most recent audited financial statements to confirm the increase from the prior year-end.
- Confirm the status and enrollment progress of the ongoing Viaskin Peanut and Viaskin Milk clinical trials.
- Review the fully diluted share count (33,004,583) to assess potential dilution from outstanding warrants and options.
- Check for any subsequent filings regarding debt issuance or capital raises that may have occurred after September 30, 2018.